Physician profile
Lance Bryson
NPI 1306388350
$4,074.84
in general payments reported to CMS, 2019-2025
28 companies · $1,277 in 2025
The $1,277 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $128 · 2022: $522 · 2023: $1,197 · 2024: $950 · 2025: $1,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,339 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,339.45 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $850.90 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $528.36 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $509.07 | 2022-2025 | Provenge |
| Astellas Pharma US INC | $330.60 | 2021-2025 | Xtandi |
| Tolmar, INC. | $257.29 | 2023-2025 | Jatenzo, Eligard |
| Myriad Genetic Laboratories, INC. | $197.23 | 2023-2024 | Prolaris |
| Janssen Biotech, INC. | $192.10 | 2023-2025 | Erleada |
| Abbvie INC. | $154.33 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.36 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $110.30 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Urogen Pharma, INC. | $98.34 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $79.86 | 2024-2025 | Adstiladrin |
| Davol INC. | $79.75 | 2023-2024 | Arista Ah Flexitip |
| Accord Healthcare, INC. | $71.11 | 2022-2023 | |
| Progenics Pharmaceuticals, INC. | $69.07 | 2023-2025 | Pylarify |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $63.83 | 2021-2023 | Caldolor |
| Myovant Sciences INC. | $49.88 | 2021-2022 | |
| Coloplast Corp | $46.25 | 2022-2025 | |
| Axonics, INC. | $39.21 | 2023 | Axonics |
| Tolmar Pharmaceuticals, INC. | $36.30 | 2022 | |
| Procept Biorobotics Corporation | $32.74 | 2025 | |
| Antares Pharma, INC. | $32.18 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Halozyme INC | $26.23 | 2023 | |
| Agiliti Surgical, INC. | $24.30 | 2023 | Trinity, Sonablate, Cryocare Cs |
| Immunitybio, INC. | $23.83 | 2025 | |
| Novo Nordisk INC | $22.95 | 2024 | Rivfloza |
| Boston Scientific Corporation | $20.18 | 2024 | Ams 700 |
| Provepharm INC. | $14.29 | 2025 | Bludigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Bryson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.